RankAlpha logo
Back to Rankings

DTIL

Precision BioSciencesB
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
View Chart
Current thesis
The constructive case is that DTIL still has two wholly owned clinical-stage in vivo gene-editing programs moving forward at once, with PBGENE-HBV producing ongoing cohort progress and PBGENE-DMD now enrolling, while management says existing cash supports multiple readouts through 2028.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +7.8.
What can break
Clinical data remain early and event-driven; unfavorable safety, efficacy, or durability signals in PBGENE-HBV or PBGENE-DMD could reset the equity sharply.
Momentum
84
Value
41
Sentiment
56
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $8.00 · Bull $14.00 · Bear $3.50
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-18 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $29.60
Why
Momentum84 · Δ7d +7.8
Value41 · Δ7d -0.1
Sentiment56 · Δ7d +8.1
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
84
26% active weight
Current posture
7d trendImproving
Δ7d
+7.8
Δ21d
+56.4
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
56
34% active weight
Current posture
7d trendImproving
Δ7d
+8.1
Δ21d
-9.5
Why this grade

Composite grade B. Momentum 83.6 / Value 41.1 / Sentiment 56.0

Fundamentals (TTM)
As of 2026-07-20
Market Cap
$189.91M
Beta
1.31
Shares Out
25.8M
P/E (TTM) · Derived
-2.0
P/S (TTM)
133.84
P/FCF (TTM) · Derived
-1.87
Rev YoY
+37272.4%
EPS YoY
-66.2%
Gross Margin
+94.0%
Op Margin
-12822.6%
Net Debt
-$86.78M
Current Ratio
14.02
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology